Table 2 Thromboembolic events by dabigatran dose and each factor

Very low-dose (75 mg twice daily)

3

23

5.73 [1.55–21.2], (0.009*)

Age, years

77.4 ± 13.5

71.0 ± 10.8

1.06 [1.01–1.12], (0.013*)

Gender, female

10

234

2.40 [0.93–6.16], (0.069)

Creatinine clearance: Ccr (mL/min)

58.9 ± 23.5

69.0 ± 25.3

0.98 [0.96–1.02], (0.096)

History of bleeding

1

78

0.46 [0.06–3.45], (0.449)

New users

8

346

1.28 [0.50–3.29], (0.604)

Change from warfarin

8

224

1.66 [0.65–4.27], (0.292)

C: Congestive heart failure

6

132

1.84 [0.67–4.99], (0.233)

H: Hypertension

9

417

0.56 [0.22–1.45], (0.231)

A: Aged 75 or older

13

281

3.16 [1.11–8.96], (0.031*)

D: Diabetes Mellitus

5

135

1.36 [0.47–3.90], (0.561)

S: Stroke/TIA (2 points)

10

175

3.24 [1.26–8.36], (0.015*)

CHADS2 score

2.94 ± 1.51

1.92 ± 1.34

1.69 [1.21–2.37], (0.002*)

With antiplatelet agents

2

127

0.55 [0.12–2.43], (0.426)